BPC‑157: proposed mechanisms of tissue repair

BPC-157 has accumulated a large experimental literature describing faster healing of tendons, muscles, skin and the gut in animal models. The harder question is why. Over the past fifteen years, several signalling pathways have been proposed. This review examines the main candidates, the experiments behind each one, and the gaps that remain before any of them can be regarded as settled.

Origins and structure

BPC-157 is a pentadecapeptide, a chain of 15 amino acids, derived from a larger protein first described in human gastric juice by researchers in Zagreb^[1]. The same group has emphasised its unusual stability: unlike most short peptides, it is reported to remain intact in human gastric juice^[2]. Its sequence is GEPPPGKPADDAGLV^[3].

The peptide has a longer clinical history than is often realised. A 2003 paper described it as being in clinical trials for inflammatory bowel disease at the time^[3], and a later review refers to its earlier use in ulcerative colitis and multiple sclerosis trials^[4]. Full results of those programmes are not reported in the sources reviewed here.

Two features of the literature shape how the mechanistic evidence should be read. First, a large proportion comes from a small number of laboratories^[5]. Second, much of it describes downstream effects, such as changes in gene expression or protein phosphorylation, rather than the first step by which the peptide acts on a cell.

Proposed mechanism one: angiogenesis through VEGFR2

New blood vessel formation is essential for repair, particularly in poorly vascularised tissues such as tendon. In 2017, researchers in Taiwan reported that BPC-157 increased vessel density in the chick chorioallantoic membrane assay and in endothelial tube formation assays. In a rat model of hind-limb ischaemia it accelerated the recovery of blood flow. These effects were associated with activation and increased expression of VEGFR2, the main receptor for vascular endothelial growth factor^[6].

This is one of the better-characterised mechanisms, because it links a cellular signal to a measurable tissue outcome in the same study.

Proposed mechanism two: nitric oxide and vascular tone

A related line of work examined nitric oxide, a signalling molecule that relaxes blood vessels and supports endothelial repair. In isolated rat aorta, BPC-157 produced concentration-dependent relaxation that depended on an intact endothelium and was blocked by inhibitors of nitric oxide synthesis. In endothelial cells it increased phosphorylation of Src, caveolin-1 and endothelial nitric oxide synthase (eNOS), and inhibiting Src abolished the effect^[7].

The proposed sequence, Src activation releasing eNOS from caveolin-1 so that it can produce nitric oxide, is plausible and well described in vascular biology. It has so far been shown for BPC-157 in isolated tissue and cultured cells rather than in injured tissue in living animals.

Proposed mechanism three: fibroblast migration and survival

Fibroblasts lay down the collagen that restores a tendon's strength. A 2011 study used tendon explants and cultured fibroblasts from rat Achilles tendon. BPC-157 accelerated the outgrowth of cells from explants, improved survival under hydrogen peroxide stress and increased migration in a dose-dependent manner. It did not directly increase proliferation. The authors linked these effects to formation of F-actin and phosphorylation of focal adhesion kinase (FAK) and paxillin, proteins that coordinate cell attachment and movement^[8].

Proposed mechanism four: growth hormone receptor expression

The same research team later used microarray analysis to look for genes changed by BPC-157 in tendon fibroblasts. The growth hormone receptor was among the most strongly up-regulated. When growth hormone was added to treated cells, proliferation increased, and the downstream kinase JAK2 was activated^[9]. The authors proposed that BPC-157 may make tendon cells more responsive to circulating growth hormone.

This is an interesting hypothesis because it could explain how BPC-157 promotes repair without directly stimulating proliferation. It has not yet been confirmed in living tissue.

Summary of the principal studies

From mechanism to tissue

Mechanistic studies sit alongside a larger body of whole-animal work. In the transected rat Achilles tendon, BPC-157 improved load to failure and other biomechanical measures, functional recovery and the histological appearance of healing tissue^[3]. Reviews from the originating group describe comparable findings in gastrointestinal lesions, including models in which standard angiogenic growth factors were less consistent^[10], and in skin wounds, burns and fistulas^[4].

An independent critical review of musculoskeletal studies found consistently positive results across tendon, ligament and muscle injury models. It also stressed that most work has been done in small rodents and that efficacy in humans had not been confirmed^[5]. A 2025 systematic review reached the same conclusion from a larger set of papers: 35 of 36 included studies were preclinical^[11].

Safety data

The most systematic toxicology study to date examined BPC-157 in mice, rats, rabbits and dogs. Single doses produced no test-related effects. In repeated-dose studies it was well tolerated, with the exception of a reversible reduction in creatinine at the highest dose in dogs. Local irritation was mild, and no genetic or embryo-fetal toxicity was observed^[12].

Human safety data are extremely limited. Only three pilot studies have been published^[13]: a retrospective telephone survey of knee injections^[14], an uncontrolled study of 12 women with interstitial cystitis^[15], and an intravenous safety study in two participants^[16]. No adverse events were reported, but samples of this size cannot detect uncommon or delayed effects.

Regulatory context

Recent reviews note that BPC-157 has not been approved for medical use by the United States Food and Drug Administration or other major regulators, because comprehensive clinical studies confirming benefit in humans are lacking^[17].

Open questions

• The initiating event. Which receptor or binding partner, if any, first recognises BPC-157 on or in a cell?
• Relative importance. Which of the proposed pathways matters most in each tissue, and do they operate together?
• Pharmacokinetics. What concentrations reach the site of injury after different routes of administration, and how do they compare with those used in cell studies?
• Replication. Can independent groups, with blinded and pre-registered designs, reproduce the key tendon and vascular findings?
• Human relevance. Do the effects seen in acute, surgically created injuries translate to chronic human conditions?

Until these questions are addressed, the pathways described here are best understood as working hypotheses. They are supported by coherent experimental data, but they are not yet a validated account of how BPC-157 works.